Recent Advances Made in Myeloma Treatment

Please Log In or Register to continue.

Release Date: January 31, 2020
Expiration Date: January 31, 2021

Expected time to complete this activity as designed: 60 minutes
There are no fees for participating in or receiving credit for this online activity.

Program Overview

In this activity, Dr. Joshua Richter and Dr. Ajai Chari provide details of the most exciting and impactful news from 2019. These experts will share their thoughts on a variety of topics, including the new interesting studies using four-drug regimens in the upfront setting like ALCYONE, GRIFFIN, and CASSIOPEIA. Additionally, this activity discusses CAR T-cell therapies, bi-specific antibodies, and antibody-drug conjugates. You can also hear what to expect this year in 2020.

Target Audience

This activity is designed for multidisciplinary healthcare providers in the community setting, including hematologists, oncologists, nurses, pharmacists and other allied healthcare professionals who provide care to patients with multiple myeloma.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Report highlights of practice changing data looking at efficacy and safety from clinical trials investigating treatment approaches across the multiple myeloma disease lifecycle, including NDMM, RRMM, and maintenance
  • Outline clinical trials and recent advances in the management of disease- and treatment-related conditions in MM
  • Summarize expert faculty perspectives on clinical trial data for emerging novel approaches to the treatment of MM, highlighted from ASCO, IMW, and ASH in 2019 including CAR T-cell therapies, bi-specific antibodies, and antibody-drug conjugates

Agenda

  • Recent Advances Made in Myeloma Treatment – Joshua Richter, MD, and Ajai Chari, MD

Instructions for Participation and Credit

This activity is eligible for credit through January 31, 2021. After this date, this activity will expire and no further credit will be awarded.

  1. Read the target audience, learning objectives, and faculty disclosures.
  2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
  3. Complete the educational content as designed.
  4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
  5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
  6. Certificates for CME and CNE may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.

Faculty Biographies

Joshua Richter, MD
Assistant Professor of Medicine
Icahn School of Medicine at Mount Sinai
Director of Myeloma
Blavatnik Family Center at Chelsea Mount Sinai
New York, New York

Dr. Joshua Richter received his medical degree from New York Medical College. He completed an internal medicine residency at St. Vincent’s Hospital – New York Medical College, and a hematology/oncology fellowship at Yale Cancer Center, Yale University. Dr. Richter served as Clinical Assistant Professor at Rutgers University, New Brunswick, New Jersey, and worked in the Division of Myeloma at the John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey. He  is Assistant Professor of Medicine at the Icahn School of Medicine at Mount Sinai and Director of Myeloma at Blavatnik Family Center at Chelsea Mount Sinai.

Dr. Richter is board certified in internal medicine, hematology, and medical oncology. He has been published in numerous oncology journals including New England Journal of Medicine, Blood, Journal of Clinical Oncology, and the British Journal of Haematology. Dr. Richter specializes in multiple myeloma as well as other plasma cell dyscrasias such as amyloidosis and Waldenstrom’s macroglobulinemia.

Ajai Chari, MD
Associate Professor of Medicine
Icahn School of Medicine at Mount Sinai
Director of Clinical Research
Multiple Myeloma Program
Mount Sinai School of Medicine
New York, New York

Dr. Ajai Chari received his medical degree from UCLA School of Medicine. He completed a residency in internal medicine at New York Presbyterian Hospital, Columbia University Medical Center, and a fellowship in hematology and oncology at the University of California, San Francisco. Dr. Chari is an Associate Professor of Medicine at Icahn School of Medicine at Mount Sinai, and Director of Clinical Research, Multiple Myeloma Program at Mount Sinai School of Medicine.

Dr. Chari is board certified in internal medicine, oncology, and hematology. He holds memberships in the American Society of Hematology, the American Society of Clinical Oncology, and the International Myeloma Working Group (IMWG), among others. His research interest is in the development of novel therapeutic agents for patients with plasma cell disorders. As a specialist in plasma cell disorders, Dr. Chari sees patients through the entire continuum of related disorders, from monoclonal gammopathies to smoldering myeloma to newly diagnosed and multi-drug refractory myeloma. He also has a large practice of rarer disorders such as AL amyloidosis and POEMS syndrome. Dr. Chari’s research and clinical efforts have resulted in numerous oral presentations at the annual meetings of ASH, ASCO, and the IMW. He has authored/coauthored 68 scientific papers, reviews and chapters, and he has served as the international and national principal investigator (PI) of numerous studies.

Accreditation

MediCom CME CREDIT
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ACPE CPE CREDIT
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 1.0 contact hour of Continuing Education Credit. Universal Activity Number: 827-0000-20-005-H01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.

International Pharmacy Preceptors and Canadian Pharmacists: If you are in need of e-Profile ID to participate in an ACPE approved activity, please contact NABP customer service for further assistance as special handling is necessary. NABP customer service can be reached at (847) 391-4406.
MediCom NURSING CREDIT
Accreditation Statement: MediCom Worldwide, Inc., 101 Washington Street, Morrisville, PA 19067 is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: 20-005-116

Disclosure

As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosures

Dr. Joshua Richter has received honoraria related to formal advisory activities from Adaptive Biotechnologies, Antengene Corporation, Bristol-Myers Squibb Company, Celgene Corporation, Janssen Pharmaceuticals, Inc., Karyopharm Therapeutics, Oncopeptides, AB, Sanofi, and Takeda Oncology, as well as speakers’ bureau activities from Celgene and Janssen.

Dr. Ajai Chari has received honoraria related to formal advisory activities from Amgen Inc., Celgene Corporation, Janssen Pharmaceuticals, Inc., Karyopharm Therapeutics, Sanofi, Seattle Genetics, Inc., and Takeda Oncology, as well as consultant fees from Amgen, Antengene Corporation, Bristol-Myers Squibb Company, Celgene, Janssen, Karyopharm, and Takeda Oncology. He has received grant support related to research activities from Amgen, Array BioPharma, Celgene, GlaxoSmithKline plc, Janssen, Novartis AG, Oncoceutics, Inc., Pharmacyclics, Inc., Seattle Genetics, and Takeda Oncology.

Planning Committee Disclosures

The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Andrea Mathis, Project Manager, and Joan Meyer, RN, MHA, Executive Director, have no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at cmettille@medicaled.com

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Celgene Corporation.

©2020 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

Please Log In or Register to continue.